GGCT and osteosarcoma: Pro-GA, as a cell membrane permeable GGCT inhibitor, might become a promising novel therapeutic agent against various cancers expressing high levels of GGCT such as breast, ovarian, cervical, lung, urinary bladder, colon cancers, osteosarcoma, esophageal squamous cell carcinoma, and glioma.